Search clinical trials for: MAB 2C4 (PERTUZUMAB)

Total 1543 results

Genentech, Inc.

Completed

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Ovarian Cancer
Genentech, Inc.

Completed

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

Prostate Cancer
SCRI Development Innovations, LLC
Genentech, Inc.

Completed

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Neuroendocrine Carcinoma

United States
Genentech, Inc.

Completed

Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors

Neoplasms

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

Breast Cancer

Australia, Spain, United Kingdom, Germany, Belgium, Italy, Finland, Netherlands
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Genentech, Inc.

Completed

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Pamela L. Kunz
Genentech, Inc.

Terminated

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroblastoma | Multiple Endocrine Neoplasia | Pancreatic Neuroendocrine Tumors | Carcinoid Tumors | Adrenal Gland Tumors

United States
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Shanghai Henlius Biotech

Completed

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
Genentech, Inc.

Completed

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Solid Cancers
Hoffmann-La Roche

Completed

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Solid Tumor

Spain, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
George Albert Fisher
Genentech, Inc.

Terminated

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Solid Tumor

United Kingdom, Netherlands
University of Washington
United States Department of Defense

Recruiting

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Zydus Lifesciences Limited

Not yet recruiting

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Metastatic Breast Cancer
National Cancer Institute (NCI)

Completed

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Stage III Colon Cancer | Stage III Rectal Cancer | Adenocarcinoma of the Colon

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
Genentech, Inc.

Completed

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Shengjing Hospital

Not yet recruiting

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Breast Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab (HELP)

HER2-positive Metastatic Breast Cancer | Previously Treated With Trastuzumab | Trastuzumab Combined With Pertuzumab and Chemotherapy

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche

Completed

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Elderly Metastatic Breast Cancer Population

Belgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
Memorial Sloan Kettering Cancer Center

Completed

Imaging With a New Agent That Finds a Cancer Protein Called HER2

HER2-positive Carcinoma | HER2-positive Primary Malignancy

United States
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche; Genentech, Inc.; Hartford HealthCare

Active, not recruiting

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Metastatic HER2-Positive Breast Cancer

United States
Institut fuer Frauengesundheit
Samsung Bioepis Co., Ltd.

Recruiting

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON)

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Female

Germany
Hospices Civils de Lyon

Not yet recruiting

PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study (PETRA)

HER-2 Positive Breast Cancer

France
Shanghai Jiao Tong University School of Medicine

Recruiting

Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Breast Cancer

China
Biocad

Recruiting

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (PREFER)

Breast Cancer

Russian Federation
Academisch Medisch Centrum - Universiteit van Amsterdam...
Roche Pharma AG

Completed

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (TRAP)

Esophageal Carcinoma

Netherlands
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
Ontario Clinical Oncology Group (OCOG)

Terminated

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (PETRA)

Breast Cancer

Canada
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Biocad

Active, not recruiting

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Breast Cancer

Russian Federation
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Breast Cancer

United States
US Oncology Research
Genentech, Inc.

Terminated

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Breast Neoplasms | Malignant Tumor of the Breast

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer

China
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)

Breast Cancer

United States, United Kingdom, France, Italy, Spain, Turkey, Brazil, India
University of California, Irvine

Active, not recruiting

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

Breast Carcinoma

United States
Helsinki University Central Hospital

Active, not recruiting

Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (BOLD-1)

Breast Cancer

Finland
University of Washington
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Completed

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Stage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu Positive

United States
Memorial Sloan Kettering Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Breast Cancer Metastases | HER2 Positive Breast

United States
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Genentech, Inc.

Approved for marketing

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

HER2-positive Breast Cancer

United States

Search clinical trials for: MAB 2C4 (PERTUZUMAB)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations